Search

Your search keyword '"Morisco, Carmine"' showing total 522 results
Start Over Author "Morisco, Carmine"
522 results on '"Morisco, Carmine"'

5. Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial

Author

Piccolo, Raffaele, Avvedimento, Marisa, Canonico, Mario Enrico, Gargiulo, Paola, Paolillo, Roberta, Conti, Valeria, Dal Piaz, Fabrizio, Filippelli, Amelia, Morisco, Carmine, Simonetti, Fiorenzo, Leone, Attilio, Marenna, Alessandra, Bruzzese, Dario, Gargiulo, Giuseppe, Stabile, Eugenio, Di Serafino, Luigi, Franzone, Anna, Cirillo, Plinio, and Esposito, Giovanni

Published
2023
Full Text
View/download PDF

7. Infiltrating macrophages amplify doxorubicin-induced cardiac damage: role of catecholamines

Author

Gambardella, Jessica, Santulli, Gaetano, Fiordelisi, Antonella, Cerasuolo, Federica Andrea, Wang, Xujun, Prevete, Nella, Sommella, Eduardo, Avvisato, Roberta, Buonaiuto, Antonietta, Altobelli, Giovanna Giuseppina, Rinaldi, Laura, Chiuso, Francesco, Feliciello, Antonio, Dal Piaz, Fabrizio, Campiglia, Pietro, Ciccarelli, Michele, Morisco, Carmine, Sadoshima, Junichi, Iaccarino, Guido, and Sorriento, Daniela

Published
2023
Full Text
View/download PDF

9. Innovative Device-Based Strategies for Managing Acute Decompensated Heart Failure

Author

Bertolone, Dario Tino, Paolisso, Pasquale, Gallinoro, Emanuele, Belmonte, Marta, Bermpeis, Konstantinos, De Colle, Cristina, Esposito, Giuseppe, Caglioni, Serena, Fabbricatore, Davide, Leone, Attilio, Valeriano, Chiara, Shumkova, Monika, Storozhenko, Tatyana, Viscusi, Michele Mattia, Botti, Giulia, Verstreken, Sofie, Morisco, Carmine, Barbato, Emanuele, Bartunek, Jozef, and Vanderheyden, Marc

Published
2023
Full Text
View/download PDF

10. HIGHER INCIDENCE OF CARDIOVASCULAR EVENTS IN A LARGE REAL-WORLD DATABASE IN THE TRIENNIUM 2020-2022 COMPARED TO A PRE-COVID TRIENNIUM IS INDEPENDENT OF CARDIOVASCULAR RISK FACTORS

Author

Battistoni, Allegra, primary, Gallo, Giovanna, additional, Morisco, Carmine, additional, Piccinocchi, Gaetano, additional, Piccinocchi, Roberto, additional, Fini, Massimo, additional, Proietti, Stefania, additional, Bonassi, Stefano, additional, Trimarco, Bruno, additional, and Volpe, Massimo, additional

Published
2024
Full Text
View/download PDF

12. Contemporary Management of Stable Coronary Artery Disease

Author

Bertolone, Dario Tino, Gallinoro, Emanuele, Esposito, Giuseppe, Paolisso, Pasquale, Bermpeis, Konstantinos, De Colle, Cristina, Fabbricatore, Davide, Mileva, Niya, Valeriano, Chiara, Munhoz, Daniel, Belmonte, Marta, Vanderheyden, Marc, Bartunek, Jozef, Sonck, Jeroen, Wyffels, Eric, Collet, Carlos, Mancusi, Costantino, Morisco, Carmine, De Luca, Nicola, De Bruyne, Bernard, and Barbato, Emanuele

Published
2022
Full Text
View/download PDF

13. Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Author

Claassens, Daniel M. F., van Dorst, Pim W. M., Vos, Gerrit J. A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W. J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean-Paul R., Dewilde, Willem J. M., Postma, Maarten J., Deneer, Vera H. M., ten Berg, Jurriën M., and Boersma, Cornelis

Published
2022
Full Text
View/download PDF

14. Obesity: the perfect storm for heart failure.

Author

Lembo, Maria, Strisciuglio, Teresa, Fonderico, Celeste, Mancusi, Costantino, Izzo, Raffaele, Trimarco, Valentina, Bellis, Alessandro, Barbato, Emanuele, Esposito, Giovanni, Morisco, Carmine, and Rubattu, Speranza

Subjects
CARDIAC arrest, EPICARDIAL adipose tissue, WEIGHT loss, NATRIURETIC peptides, CARDIOVASCULAR system
Abstract

Obesity condition causes morphological and functional alterations involving the cardiovascular system. These can represent the substrates for different cardiovascular diseases, such as atrial fibrillation, coronary artery disease, sudden cardiac death, and heart failure (HF) with both preserved ejection fraction (EF) and reduced EF. Different pathogenetic mechanisms may help to explain the association between obesity and HF including left ventricular remodelling and epicardial fat accumulation, endothelial dysfunction, and coronary microvascular dysfunction. Multi‐imaging modalities are required for appropriate recognition of subclinical systolic dysfunction typically associated with obesity, with echocardiography being the most cost‐effective technique. Therapeutic approach in patients with obesity and HF is challenging, particularly regarding patients with preserved EF in which few strategies with high level of evidence are available. Weight loss is of extreme importance in patients with obesity and HF, being a primary therapeutic intervention. Sodium–glucose co‐transporter‐2 inhibitors have been recently introduced as a novel tool in the management of HF patients. The present review aims at analysing the most recent studies supporting pathogenesis, diagnosis, and management in patients with obesity and HF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Persistent increase of cardiovascular and cerebrovascular events in COVID-19 patients: a 3-year population-based analysis.

Author

Battistoni, Allegra, Volpe, Massimo, Morisco, Carmine, Piccinocchi, Gaetano, Piccinocchi, Roberto, Fini, Massimo, Proietti, Stefania, Bonassi, Stefano, and Trimarco, Bruno

Subjects
COVID-19, CEREBROVASCULAR disease, GENERAL practitioners
Abstract

Aims We evaluated the incidence and relative risk of major post-acute cardiovascular consequences of SARS-CoV-2 infection in a large real-world population from a primary care database in a region at moderate cardiovascular risk followed up in the period 2020–22. Methods and results This is a retrospective cohort analysis using data from a cooperative of general practitioners in Italy. Individuals aged >18 affected by COVID-19 starting from January 2020 have been followed up for 3 years. Anonymized data from 228 266 patients in the period 2020–22 were considered for statistical analysis and included 31 764 subjects with a diagnosis of COVID-19. An equal group of subjects recorded in the same database in the period 2017–19 was used as propensity score-matched comparison as an unquestionable COVID-19-free population. Out of the 228 266 individuals included in the COMEGEN database during 2020–22, 31 764 (13.9%) were ascertained positive with SARS-CoV-2 infection by a molecular test reported to general practitioners. The proportion of individuals with a new diagnosis of major adverse cardiovascular and cerebrovascular events was higher in the 2020–22 COVID-19 group than in the 2017–19 COMEGEN propensity score-matched comparator, with an odds ratio of 1.73 (95% confidence interval: 1.53–1.94; P < 0.001). All major adverse cardiovascular and cerebrovascular events considered showed a significantly higher risk in COVID-19 individuals. Incidence calculated for each 6-month period after the diagnosis of COVID-19 in our population was the highest in the first year (1.39% and 1.45%, respectively), although it remained significantly higher than in the COVID-19-free patients throughout the 3 years. Conclusion The increase of cardiovascular risk associated with COVID-19 might be extended for years and not limited to the acute phase of the infection. This should promote the planning of longer follow-up for COVID-19 patients to prevent and promptly manage the potential occurrence of major adverse cardiovascular and cerebrovascular events. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Achieving a Systolic Blood Pressure Below 130 mmHg Reduces the Incidence of Cardiovascular Events in Hypertensive Patients with Echocardiographic Left Ventricular Hypertrophy

Author

Lembo, Maria, primary, Trimarco, Valentina, additional, Izzo, Raffaele, additional, Manzi, Maria Virginia, additional, Rozza, Francesco, additional, Gallo, Paola, additional, Morisco, Carmine, additional, Bardi, Luca, additional, Esposito, Giovanni, additional, Forzano, Imma, additional, Santulli, Gaetano, additional, and Trimarco, Bruno, additional

Published
2023
Full Text
View/download PDF

24. Macrophages participate in doxorubicin-induced cardiac damage

Author

Cerasuolo, Federica Andrea, Gambardella, Jessica, Santulli, Gaetano, Fiordelisi, Antonella, Wang, Xujun, Prevete, Nella, Sommella, Edoardo, Avvisato, Roberta, Buonaiuto, Antonietta, Altobelli, Giovanna Giuseppina, Ciccarelli, Michele, Morisco, Carmine, Sadoshima, Junichi, Iaccarino, Guido, and Sorriento, Daniela

Published
2024
Full Text
View/download PDF

27. The therapeutic concordance approach reduces adverse drug reactions in patients with resistant hypertension

Author

Trimarco, Valentina, Manzi, Maria Virginia, Izzo, Raffaele, Mone, Pasquale, Lembo, Maria, Pacella, Daniela, Esposito, Giovanni, Falco, Angela, Morisco, Carmine, Gallo, Paola, Santulli, Gaetano, Trimarco, Bruno, Trimarco, Valentina, Manzi, Maria Virginia, Izzo, Raffaele, Mone, Pasquale, Lembo, Maria, Pacella, Daniela, Esposito, Giovanni, Falco, Angela, Morisco, Carmine, Gallo, Paola, Santulli, Gaetano, and Trimarco, Bruno

Subjects
concordance, adverse drug reactions, hypertension, adverse drug reaction, adherence, blood pressure, compliance, pharmacologic resistance, resistant hypertension, Cardiology and Cardiovascular Medicine
Abstract

BackgroundAdverse drug reactions (ADRs) remain among the leading causes of therapy-resistant hypertension (TRH) and uncontrolled blood pressure (BP). We have recently reported beneficial results in BP control in patients with TRH adopting an innovative approach, defined as therapeutic concordance, in which trained physicians and pharmacists reach a concordance with patients to make them more involved in the therapeutic decision-making process.MethodsThe main scope of this study was to investigate whether the therapeutic concordance approach could lead to a reduction in ADR occurrence in TRH patients. The study was performed in a large population of hypertensive subjects of the Campania Salute Network in Italy (ClinicalTrials.gov Identifier: NCT02211365).ResultsWe enrolled 4,943 patients who were firstly followed-up for 77.64 ± 34.44 months, allowing us to identify 564 subjects with TRH. Then, 282 of these patients agreed to participate in an investigation to test the impact of the therapeutic concordance approach on ADRs. At the end of this investigation, which had a follow-up of 91.91 ± 54.7 months, 213 patients (75.5%) remained uncontrolled while 69 patients (24.5%, p ConclusionOur findings indicate that the therapeutic concordance approach significantly reduces ADRs in TRH patients.

Published
2023

28. Left Ventricular Mechano-Energetic Efficiency Identifies an Early Impairment of Myocardial Blood Flow in Arterial Hypertension

Author

Lembo, Maria, primary, Acampa, Wanda, additional, Elena Rao, Maria Assunta, additional, Manzi, Maria Virginia, additional, Morisco, Carmine, additional, Esposito, Giovanni, additional, Assante, Roberta, additional, Zampella, Emilia, additional, Nappi, Carmela, additional, Gaudieri, Valeria, additional, Mannarino, Teresa, additional, Mancusi, Costantino, additional, de Simone, Giovanni, additional, Izzo, Raffaele, additional, Cuocolo, Alberto, additional, and Trimarco, Bruno, additional

Published
2023
Full Text
View/download PDF

29. The therapeutic concordance approach reduces adverse drug reactions in patients with resistant hypertension

Author

Trimarco, Valentina, primary, Manzi, Maria Virginia, additional, Izzo, Raffaele, additional, Mone, Pasquale, additional, Lembo, Maria, additional, Pacella, Daniela, additional, Esposito, Giovanni, additional, Falco, Angela, additional, Morisco, Carmine, additional, Gallo, Paola, additional, Santulli, Gaetano, additional, and Trimarco, Bruno, additional

Published
2023
Full Text
View/download PDF

30. Abstract 16390: Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients

Author

Claassens, Danny M, Vos, Gerrit J, Boersma, Cornelis, Bergmeijer, Thomas, Hermanides, Rik, van t Hof, Arnoud, Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M, Asselbergs, Folkert W, Mosterd, Arend, Herrman, Jean-Paul, Dewilde, Willem, Postma, Maarten J, Deneer, Vera H, and ten berg, jurrien m

Published
2020
Full Text
View/download PDF

36. Supplementary Data from Haploinsufficiency of the Hmga1 Gene Causes Cardiac Hypertrophy and Myelo-Lymphoproliferative Disorders in Mice

Author

Fedele, Monica, primary, Fidanza, Vincenzo, primary, Battista, Sabrina, primary, Pentimalli, Francesca, primary, Klein-Szanto, Andres J.P., primary, Visone, Rosa, primary, De Martino, Ivana, primary, Curcio, Antonio, primary, Morisco, Carmine, primary, Del Vecchio, Luigi, primary, Baldassarre, Gustavo, primary, Arra, Claudio, primary, Viglietto, Giuseppe, primary, Indolfi, Ciro, primary, Croce, Carlo M., primary, and Fusco, Alfredo, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure S1 from Haploinsufficiency of the Hmga1 Gene Causes Cardiac Hypertrophy and Myelo-Lymphoproliferative Disorders in Mice

Author

Fedele, Monica, primary, Fidanza, Vincenzo, primary, Battista, Sabrina, primary, Pentimalli, Francesca, primary, Klein-Szanto, Andres J.P., primary, Visone, Rosa, primary, De Martino, Ivana, primary, Curcio, Antonio, primary, Morisco, Carmine, primary, Del Vecchio, Luigi, primary, Baldassarre, Gustavo, primary, Arra, Claudio, primary, Viglietto, Giuseppe, primary, Indolfi, Ciro, primary, Croce, Carlo M., primary, and Fusco, Alfredo, primary

Published
2023
Full Text
View/download PDF

38. Therapeutic concordance improves blood pressure control in patients with resistant hypertension

Author

Trimarco, Valentina, primary, Izzo, Raffaele, additional, Mone, Pasquale, additional, Lembo, Maria, additional, Manzi, Maria Virginia, additional, Pacella, Daniela, additional, Falco, Angela, additional, Gallo, Paola, additional, Esposito, Giovanni, additional, Morisco, Carmine, additional, Santulli, Gaetano, additional, and Trimarco, Bruno, additional

Published
2023
Full Text
View/download PDF

40. 150 ECHO-DERIVED LEFT VENTRICULAR MECHANO-ENERGETIC EFFICACY CHARACTERIZES HYPERTENSIVE PATIENTS WITH IMPAIRED PET-DERIVED MYOCARDIAL BLOOD FLOW

Author

Lembo, Maria, primary, Acampa, Wanda, additional, Elena Rao, Maria Assunta, additional, Virginia Manzi, Maria, additional, Morisco, Carmine, additional, Mancusi, Costantino, additional, Esposito, Giovanni, additional, Cuocolo, Alberto, additional, Izzo, Raffaele, additional, and Trimarco, Bruno, additional

Published
2022
Full Text
View/download PDF

46. A Genotype-Guided Strategy for Oral P2Y(12) Inhibitors in Primary PCI

Author

Claassens, Daniel M F, Vos, Gerrit J A, Bergmeijer, Thomas O, Hermanides, Renicus S, van 't Hof, Arnoud W J, van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M, Asselbergs, Folkert W, Mosterd, Arend, Herrman, Jean-Paul R, Dewilde, Willem J M, Janssen, Paul W A, Kelder, Johannes C, Postma, Maarten J, de Boer, Anthonius, Boersma, Cornelis, Deneer, Vera H M, Ten Berg, Jurriën M, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, RS: Carim - H01 Clinical atrial fibrillation, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: CARIM - R2.01 - Clinical atrial fibrillation, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Cardiovascular Centre (CVC), Value, Affordability and Sustainability (VALUE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Microbes in Health and Disease (MHD), PharmacoTherapy, -Epidemiology and -Economics, Methods in Medicines evaluation & Outcomes research (M2O), Claassens, Daniel M F, Vos, Gerrit J A, Bergmeijer, Thomas O, Hermanides, Renicus S, van 't Hof, Arnoud W J, van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M, Asselbergs, Folkert W, Mosterd, Arend, Herrman, Jean-Paul R, Dewilde, Willem J M, Janssen, Paul W A, Kelder, Johannes C, Postma, Maarten J, de Boer, Anthoniu, Boersma, Corneli, Deneer, Vera H M, and Ten Berg, Jurriën M

Subjects
Male, medicine.medical_treatment, MULTICENTER, Administration, Oral, 030204 cardiovascular system & hematology, Clopidogrel/adverse effects, law.invention, 0302 clinical medicine, P2Y12, Randomized controlled trial, law, Hemorrhage/chemically induced, Genotype, Taverne, Single-Blind Method, ST-SEGMENT ELEVATION, 030212 general & internal medicine, Precision Medicine, Non-U.S. Gov't, Medicine(all), OUTCOMES, Research Support, Non-U.S. Gov't, DUAL ANTIPLATELET THERAPY, General Medicine, Middle Aged, Clopidogrel, Prasugrel Hydrochloride/adverse effects, OPEN-LABEL, Intention to Treat Analysis, Coronary Thrombosis/prevention & control, Multicenter Study, Ticagrelor/adverse effects, CYP2C19 GENOTYPE, CLOPIDOGREL, Administration, Purinergic P2Y Receptor Antagonists/adverse effects, Randomized Controlled Trial, Female, Stents, medicine.drug, Oral, medicine.medical_specialty, ST Elevation Myocardial Infarction/drug therapy, PERCUTANEOUS CORONARY INTERVENTION, Research Support, 03 medical and health sciences, Percutaneous Coronary Intervention, Internal medicine, STENT THROMBOSIS, medicine, Journal Article, Humans, Aged, Intention-to-treat analysis, business.industry, ELEVATION MYOCARDIAL-INFARCTION, Percutaneous coronary intervention, Precision medicine, Conventional PCI, business, Cytochrome P-450 CYP2C19/genetics
Abstract

BackgroundIt is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y(12) inhibitors.MethodsWe conducted a randomized, open-label, assessor-blinded trial in which patients undergoing primary PCI with stent implantation were assigned in a 1:1 ratio to receive either a P2Y(12) inhibitor on the basis of early CYP2C19 genetic testing (genotype-guided group) or standard treatment with either ticagrelor or prasugrel (standard-treatment group) for 12 months. In the genotype-guided group, carriers of CYP2C19*2 or CYP2C19*3 loss-of-function alleles received ticagrelor or prasugrel, and noncarriers received clopidogrel. The two primary outcomes were net adverse clinical events - defined as death from any cause, myocardial infarction, definite stent thrombosis, stroke, or major bleeding defined according to Platelet Inhibition and Patient Outcomes (PLATO) criteria - at 12 months (primary combined outcome; tested for noninferiority, with a noninferiority margin of 2 percentage points for the absolute difference) and PLATO major or minor bleeding at 12 months (primary bleeding outcome).ResultsFor the primary analysis, 2488 patients were included: 1242 in the genotype-guided group and 1246 in the standard-treatment group. The primary combined outcome occurred in 63 patients (5.1%) in the genotype-guided group and in 73 patients (5.9%) in the standard-treatment group (absolute difference, -0.7 percentage points; 95% confidence interval [CI], -2.0 to 0.7; PConclusionsIn patients undergoing primary PCI, a CYP2C19 genotype-guided strategy for selection of oral P2Y(12) inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding. (Funded by the Netherlands Organization for Health Research and Development; POPular Genetics ClinicalTrials.gov number, NCT01761786; Netherlands Trial Register number, NL2872.)Patients undergoing primary PCI were randomly assigned to either a genotype-guided strategy for selecting a P2Y(12) inhibitor or to standard treatment with ticagrelor or prasugrel. At 12 months, genotype-guided therapy was noninferior to standard treatment with respect to thrombotic events and resulted in a lower incidence of bleeding.

Published
2019

48. Insulin Resistance and Vitamin D Deficiency: A Link Beyond the Appearances

Author

Trimarco, Valentina, primary, Manzi, Maria Virginia, additional, Mancusi, Costantino, additional, Strisciuglio, Teresa, additional, Fucile, Ilaria, additional, Fiordelisi, Antonella, additional, Pilato, Emanuele, additional, Izzo, Raffaele, additional, Barbato, Emanuele, additional, Lembo, Maria, additional, and Morisco, Carmine, additional

Published
2022
Full Text
View/download PDF

50. Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial

Author

Piccolo, Raffaele, primary, Avvedimento, Marisa, additional, Canonico, Mario Enrico, additional, Gargiulo, Paola, additional, Paolillo, Roberta, additional, Conti, Valeria, additional, Dal Piaz, Fabrizio, additional, Filippelli, Amelia, additional, Morisco, Carmine, additional, Simonetti, Fiorenzo, additional, Leone, Attilio, additional, Marenna, Alessandra, additional, Bruzzese, Dario, additional, Gargiulo, Giuseppe, additional, Stabile, Eugenio, additional, Di Serafino, Luigi, additional, Franzone, Anna, additional, Cirillo, Plinio, additional, and Esposito, Giovanni, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results